American Journal of Ophthalmology
Volume 149, Issue 1 , Pages 4-6.e2 , January 2010

When Should Anti-Vascular Endothelial Growth Factor Treatment Be Stopped in Age-Related Macular Degeneration?

  • Alain Gaudric

      Affiliations

    • Service d'Ophtalmologie, Hôpital Lariboisière, Assistance Publique–Hôpitaux de Paris and Université Paris 7 Diderot, Paris, France
    • Corresponding Author InformationInquiries to Alain Gaudric, MD, Service d'Ophtalmologie, Hôpital Lariboisière, 2 rue Ambroise Paré, 75010 Paris
    • ,
  • Salomon Y. Cohen

      Affiliations

    • Service d'Ophtalmologie, Hôpital Lariboisière, Assistance Publique–Hôpitaux de Paris and Université Paris 7 Diderot, Paris, France
    • Centre Ophtalmologique d'Imagerie et de Laser, Paris, France

,Accepted 31 August 2009.

References 

  1. Ip MS, Scott IU, Brown GC, et al. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology. Ophthalmology. 2008;115:1837–1846
  2. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–1444
  3. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–1431
  4. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009;116:57–65
  5. Moreno SF, Paloma JB. Therapeutic anti-VEGF in age-related macular degeneration: Ranibizumab and Bevacizumab controversy. Br J Ophthalmol. 2008;92:866–867
  6. Packer S, Jampol LM. An ethical view of the ranibizumab and bevacizumab controversy. Arch Ophthalmol. 2008;126:286;author reply 286–287
  7. Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials–TAP report 2. Arch Ophthalmol. 2001;119:198–207
  8. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143:566–583
  9. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: Year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148:43–58
  10. Spaide R. The as-needed treatment strategy for choroidal neovascularization: a feedback-based treatment system. Am J Ophthalmol. 2009;148:1–3
  11. Amoaku W. Ranibizumab: The clinician's guide to commencing, continuing, and discontinuing treatment. Eye. 2009;23:2140–2142
  12. Chang LK, Sarraf D. Tears of the retinal pigment epithelium: an old problem in a new era. Retina. 2007;27:523–534
  13. Smith BT, Kraus CL, Apte RS. Retinal pigment epithelial tears in ranibizumab-treated eyes. Retina. 2009;29:335–339
  14. Schmidt-Erfurth U, Wolf S. Same-day administration of verteporfin and ranibizumab 0.5 mg in patients with choroidal neovascularisation due to age-related macular degeneration. Br J Ophthalmol. 2008;92:1628–1635
  15. Cohen SY, Dubois L, Tadayoni R, et al. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. Am J Ophthalmol. 2009;148:409–413
  16. Spaide R. Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol. 2007;143:679–680

PII: S0002-9394(09)00670-9

doi: 10.1016/j.ajo.2009.08.039

American Journal of Ophthalmology
Volume 149, Issue 1 , Pages 4-6.e2 , January 2010

Article Tools